Japan Drug Makers Move To Biotech Generics Under New Rules
This article was originally published in PharmAsia News
Executive SummaryJapanese drug makers seek to take advantage of new government drug guidelines to develop and market their own generic versions of drugs based on biotechnology. Such drugs often are more expensive to produce than conventional drugs because of the genetic engineering and other techniques involved. Aska Pharmaceutical, which specializes in gynecological medicines, and JCR Pharmaceuticals, which concentrates on cell cultivation, plan a joint trial of an infertility generic, possibly next year. Biotech generics are expected to cost about 30 percent less than innovative ones as a result of the new guidelines. (Click here for more - a subscription may be required
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.